Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.85 |
| ▸ | MMP9 | P14780 | 3/20 | 0.85 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.85 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.85 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.85 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.85 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.85 |
| ▸ | STAT3 | P40763 | 2/20 | 0.85 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.85 |
| ▸ | RELA | Q04206 | 2/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.85 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.85 |
| ▸ | KDR | P35968 | 1/20 | 0.85 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851311 | 1.00 | APP (0.85) | APPPTGS2MMP9PRKCEPRKCQ | |
| SCHEMBL3851319 | 1.00 | APP (0.85) | APPPTGS2MMP9PRKCEPRKCQ | |
| Curcumin Pyrazole SCHEMBL9553585 | 0.92 | APP (1.00) | APPPTGS2MMP9PRKCEPRKCQ | |
| Curcumin Pyrazole SCHEMBL29798918 | 0.92 | APP (1.00) | APPPTGS2MMP9PRKCEPRKCQ | |
| Curcumin Pyrazole SCHEMBL13907614 | 0.92 | APP (1.00) | APPPTGS2MMP9PRKCEPRKCQ | |
| SCHEMBL1790052 | 0.89 | APP (0.88) | APPPTGS2MMP9PRKCEPRKCQ | |
| SCHEMBL1790054 | 0.89 | APP (0.88) | APPPTGS2MMP9PRKCEPRKCQ | |
| SCHEMBL1790057 | 0.89 | APP (0.88) | APPPTGS2MMP9PRKCEPRKCQ | |
| SCHEMBL3852579 | 0.88 | APP (0.85) | APPPTGS2MMP9PRKCEPRKCQ | |
| SCHEMBL3852583 | 0.88 | APP (0.85) | APPPTGS2MMP9PRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797072-A4 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-09-09 | — | — | EP | claimed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| EP-1797072-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033943-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2006-03-30 | — | — | WO | claimed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | APP 3265/4885PTGS2 768/4885MMP9 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.